Click here for slides on this topic


Very long-acting insulin

A type of insulin that starts to lower blood glucose within 1 hour after injection and keeps working evenly for 24 hours after injection.
The following content matched the glossary term: Very long-acting insulin

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 1 Diabetes Pharmacologic Therapy

Top

Type 1 diabetes treatment options from the 2016 ADA guidelines

ADA 2016 Insulin & Glucose Monitoring

Top

Recommendations for insulin and glucose monitoring in diabetes (SMBG) from the 2016 ADA guidelines

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

Top

Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once weekly glucagon like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78. OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).

1 2 Next 

Slide Library Results

Search Results for: Very long-acting insulin Slides Found: 5
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Diabetes Pregnancy Guidelines Insulin Therapy | NDEI
Diabetes Pregnancy Guidelines Preconception Insulin | NDEI
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI